<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02957305</url>
  </required_header>
  <id_info>
    <org_study_id>160309</org_study_id>
    <nct_id>NCT02957305</nct_id>
  </id_info>
  <brief_title>Misoprostol 400 µg Versus 200 µg for Cervical Ripening in 1st Trimester Miscarriage</brief_title>
  <acronym>MISO200</acronym>
  <official_title>Comparison Between 400 µg or 200 µg of Misoprostol for Cervical Dilatation in 1st Trimester Miscarriage - A Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Local current protocol for cervical ripening in 1st trimester miscarriage recommends 400 µg&#xD;
      of misoprostol intravaginally 3 hours before uterine evacuation. This regime has been&#xD;
      recommended by some international guidelines . So far, there are no recent studies comparing&#xD;
      cervical dilatation between 400 µg of misoprostol and a reduced dose (e.g., 200 µg) for 6&#xD;
      hours. If cervical ripening is similar between these two regimens(i.e., 200µg regimen is not&#xD;
      inferior to 400µg regimen), costs reductions and lower side effects may be issued without&#xD;
      losing quality of cervix dilatation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Miscarriage is defined by the World Health Organization as the interruption of the pregnancy&#xD;
      up to 20-23 weeks, or the products of pregnancy weighing less than 500 grams (1). Nearly 15%&#xD;
      of known pregnancies end in miscarriage, especially in the first 12 weeks. Estimates indicate&#xD;
      that 68000 women die worldwide each year, as a result of unsafe abortions. Abortions are the&#xD;
      major cause of maternal death, particularly in Latin America and the Caribbean. In cases of&#xD;
      retained and incomplete abortions, uterine emptying is recommended. In the first trimester of&#xD;
      pregnancy, either pharmacological or surgical procedure is accepted according to&#xD;
      international guidelines.&#xD;
&#xD;
      Pharmacological treatment for uterine evacuation includes the administration of mifepristone&#xD;
      and misoprostol or misoprostol alone. Nevertheless, surgical methods have been shown a&#xD;
      greater acceptability and patient satisfaction due to a reduced incidence of adverse effects.&#xD;
      Currently, Manual Vacuum Aspiration (MVA) is the technique recommended by the Brazilian&#xD;
      Ministry of Health and the Brazilian Federation of Gynecology and Obstetrics.&#xD;
&#xD;
      MVA should be performed after cervical ripening. This pre-surgical procedure makes the&#xD;
      procedure safer and more effective. In Brazil, misoprostol is the most suitable drug to be&#xD;
      used in these cases because of its efficacy, ease of use, low cost, stability at room&#xD;
      temperature, and availability. Misoprostol is a synthetic prostaglandin E1 analog and can be&#xD;
      administered by oral, sublingual, buccal, rectal, and vaginal routes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 21, 2016</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">October 19, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Patients, operators and statistical analysis were performed blindly.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Required Cervix Dilation at Initiation of the Manual Vacuum Aspiration</measure>
    <time_frame>baseline at initiation of the Manual Vacuum Aspiration</time_frame>
    <description>this outcome identifies patients that had to have a mechanical dilator for opening the cervix to perform appropriate Manual Vacuum Aspiration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Presence of a Uterine Cervical Canal With ≥8 mm of Dilation</measure>
    <time_frame>Baseline before Manual Vacuum Aspiration procedure</time_frame>
    <description>This outcome measures how many mm of dilation the cervical canal has before the procedure. Cervical permeability (≥8 mm of dilation, used as a cut-off) was measured using Karman cannulas, from higher to low diameter.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pain Score (VAS)</measure>
    <time_frame>before Manual Vacuum Aspiration</time_frame>
    <description>Pain scores were assessed using a verbal analog scale (VAS), ranging from zero (no pain) to 10 (worst possible pain)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">211</enrollment>
  <condition>Miscarriage in First Trimester</condition>
  <arm_group>
    <arm_group_label>Misoprostol 400 µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received misoprostol 400 µg: 2 tablets of misoprostol (200µg each) introduced into the vagina, at least 6 hours before the Manual Vacuum Aspiration (MVA) procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Misoprostol 200 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received misoprostol 200 µg: 1 tablet of misoprostol introduced into the vagina, at least 6 hours before the Manual Vacuum Aspiration procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol 400mcg Tab</intervention_name>
    <description>400µg of misoprostol (2 tablets)</description>
    <arm_group_label>Misoprostol 400 µg</arm_group_label>
    <other_name>Misoprostol control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol 200mcg Tab</intervention_name>
    <description>200µg of misoprostol (1 tablet)</description>
    <arm_group_label>Misoprostol 200 µg</arm_group_label>
    <other_name>Misoprostol comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients admitted at the Gynecological emergency Unit at Hospital de Clínicas de&#xD;
             Porto Alegre scheduled for uterine evacuation with &lt;12 weeks of gestation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients who do not wish to participate in the project;&#xD;
&#xD;
          -  patients with ectopic pregnancy;&#xD;
&#xD;
          -  patients with comorbidities (heart failure congestive, chronic obstructive pulmonary&#xD;
             disease);&#xD;
&#xD;
          -  patients with hypovolemic shock;&#xD;
&#xD;
          -  patients with cervical incompetence;&#xD;
&#xD;
          -  patients with infected miscarriage/abortion (presence of fever, pus from the cervix,&#xD;
             leukocytosis [&gt; 14000]);&#xD;
&#xD;
          -  patients with twin pregnancy;&#xD;
&#xD;
          -  patients with Marfan syndrome;&#xD;
&#xD;
          -  patients allergic to misoprostol;&#xD;
&#xD;
          -  patients with coagulopathy;&#xD;
&#xD;
          -  patients with opening of cervical internal os (4 mm of dilatation at the time of&#xD;
             consultation);&#xD;
&#xD;
          -  patients with previous surgery of the cervix (conization);&#xD;
&#xD;
          -  patients with concomitant use of IUDs.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo F Ricardo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HCPA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HCPA</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Kapp N, Lohr PA, Ngo TD, Hayes JL. Cervical preparation for first trimester surgical abortion. Cochrane Database Syst Rev. 2010 Feb 17;(2):CD007207. doi: 10.1002/14651858.CD007207.pub2. Review.</citation>
    <PMID>20166091</PMID>
  </reference>
  <reference>
    <citation>Blanchard K, Clark S, Winikoff B, Gaines G, Kabani G, Shannon C. Misoprostol for women's health: a review. Obstet Gynecol. 2002 Feb;99(2):316-32. Review.</citation>
    <PMID>11814515</PMID>
  </reference>
  <reference>
    <citation>Marret H, Simon E, Beucher G, Dreyfus M, Gaudineau A, Vayssière C, Lesavre M, Pluchon M, Winer N, Fernandez H, Aubert J, Bejan-Angoulvant T, Jonville-Bera AP, Clouqueur E, Houfflin-Debarge V, Garrigue A, Pierre F; Collège national des gynécologues obstétriciens français. Overview and expert assessment of off-label use of misoprostol in obstetrics and gynaecology: review and report by the Collège national des gynécologues obstétriciens français. Eur J Obstet Gynecol Reprod Biol. 2015 Apr;187:80-4. doi: 10.1016/j.ejogrb.2015.01.018. Epub 2015 Jan 31. Review.</citation>
    <PMID>25701235</PMID>
  </reference>
  <reference>
    <citation>National Collaborating Centre for Women's and Children's Health (UK). Ectopic Pregnancy and Miscarriage: Diagnosis and Initial Management in Early Pregnancy of Ectopic Pregnancy and Miscarriage. London: RCOG; 2012 Dec.</citation>
    <PMID>23638497</PMID>
  </reference>
  <reference>
    <citation>ACOG Committee Opinion. American College of Obstetrician and Gynecologist. ACOG Committee Opinion. Number 283, May 2003. New U.S. Food and Drug Administration labeling on Cytotec (misoprostol) use and pregnancy. Obstet Gynecol. 2003 May;101(5 Pt 1):1049-50.</citation>
    <PMID>12738178</PMID>
  </reference>
  <reference>
    <citation>Tang J, Kapp N, Dragoman M, de Souza JP. WHO recommendations for misoprostol use for obstetric and gynecologic indications. Int J Gynaecol Obstet. 2013 May;121(2):186-9. doi: 10.1016/j.ijgo.2012.12.009. Epub 2013 Feb 19.</citation>
    <PMID>23433680</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 4, 2016</study_first_submitted>
  <study_first_submitted_qc>November 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2016</study_first_posted>
  <results_first_submitted>July 9, 2020</results_first_submitted>
  <results_first_submitted_qc>August 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 3, 2020</results_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Clinicas de Porto Alegre</investigator_affiliation>
    <investigator_full_name>Ricardo Francalacci Savaris</investigator_full_name>
    <investigator_title>Head of the Gynecologic Emergency Unit</investigator_title>
  </responsible_party>
  <keyword>misoprostol</keyword>
  <keyword>miscarriage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We intend to share raw data with other researchers</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>unlimited</ipd_time_frame>
    <ipd_access_criteria>free to read</ipd_access_criteria>
    <ipd_url>https://docs.google.com/spreadsheets/d/1WmVYj6LDAHrOqiCaAlq4TmHg8lhFxoucxqewNfOVVkE/edit?usp=sharing</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form: English version 2020 NCT02957305</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 28, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT02957305/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with diagnosis of miscarriage and scheduled for Manual Vacuum Aspiration at the Gynecologic Emergency Unit of Hospital de Clínicas de Porto Alegre, a tertiary teaching hospital, were recruited. The first participant was enrolled on December 21, 2016.</recruitment_details>
      <pre_assignment_details>A total of 269 were screened. From these, 211 were enrolled and randomized to treatment. After randomization, 2 cases, one case of infected abortion and one case with previous cervical conization were identified and they were treated as for intention to treat.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Misoprostol 400µg</title>
          <description>Participants received misoprostol 400 µg: 2 tablets of misoprostol (200µg each) were introduced into the vagina, at least 6 hours before the Manual Vacuum Aspiration procedure.&#xD;
Misoprostol: 400µg</description>
        </group>
        <group group_id="P2">
          <title>Misoprostol 200µg</title>
          <description>Participants received misoprostol 200 µg: 1 tablet was introduced into the vagina, at least 6 hours before the Manual Vacuum Aspiration procedure.&#xD;
Misoprostol: 200µg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Misoprostol 400 µg</title>
          <description>Misoprostol 400 µg 6 hours before Manual Vacuum Aspiration</description>
        </group>
        <group group_id="B2">
          <title>Misoprostol 200</title>
          <description>Misoprostol 200 µg 6 hours before Manual Vacuum Aspiration</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="106"/>
            <count group_id="B2" value="105"/>
            <count group_id="B3" value="211"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" lower_limit="16" upper_limit="46"/>
                    <measurement group_id="B2" value="31" lower_limit="15" upper_limit="49"/>
                    <measurement group_id="B3" value="30" lower_limit="15" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="211"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazilian indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Obstetric history</title>
          <description>Obstetric history was assessed as the median number of previous miscarriages, median number of previous deliveries post 20 weeks gestation (para/parity), median number of previous pregnancies (gesta/gravida) AND median number of previous deliveries before 20 weeks gestation (miscarriages); all of them used the full range</description>
          <units>cases</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Gesta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="B2" value="2" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="B3" value="2" lower_limit="1" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Para</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" lower_limit="0" upper_limit="7"/>
                    <measurement group_id="B2" value="1" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="B3" value="1" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Miscarriages</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="B2" value="1" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="B3" value="1" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from misoprostol to procedure</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.38" spread="1.47"/>
                    <measurement group_id="B2" value="6.37" spread="1.28"/>
                    <measurement group_id="B3" value="6.37" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational age</title>
          <description>weeks of pregnancy</description>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" spread="1.4"/>
                    <measurement group_id="B2" value="7.1" spread="1.5"/>
                    <measurement group_id="B3" value="7.1" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Required Cervix Dilation at Initiation of the Manual Vacuum Aspiration</title>
        <description>this outcome identifies patients that had to have a mechanical dilator for opening the cervix to perform appropriate Manual Vacuum Aspiration</description>
        <time_frame>baseline at initiation of the Manual Vacuum Aspiration</time_frame>
        <population>Intention to Treat Population (all participants assigned to misoprostol 400µg or 200µg)</population>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol 400 µg</title>
            <description>Misoprostol 400 µg 6 hours before intrauterine suction&#xD;
Misoprostol 400 µg: evaluate the required cervix dilation in the moment of the intrauterine suction</description>
          </group>
          <group group_id="O2">
            <title>Misoprostol 200 µg</title>
            <description>Misoprostol 200 µg 6 hours before intrauterine suction&#xD;
Misoprostol 200 µg: evaluate the required cervix dilation in the moment of the intrauterine suction</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Required Cervix Dilation at Initiation of the Manual Vacuum Aspiration</title>
          <description>this outcome identifies patients that had to have a mechanical dilator for opening the cervix to perform appropriate Manual Vacuum Aspiration</description>
          <population>Intention to Treat Population (all participants assigned to misoprostol 400µg or 200µg)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>It was necessary (inadequate cervix dilation)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>It was not necessary (adequate cervix dilation)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>If there is a true difference in favour of the standard treatment of 10% (96% vs 86%), then 184 patients are required to be 95% sure that the upper limit of a one-sided 97.5% confidence interval (or equivalently a 95% two-sided confidence interval) will exclude a difference in favour of the standard group of more than 25%</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>400µg of misoprostol yields a 96% cervical dilation &gt; 8 mm. We considered 86% of the 200 µg misoprostol group as the minimal acceptable percentage. The non-inferiority margin was determined by 24.46.</non_inferiority_desc>
            <p_value>0.025</p_value>
            <p_value_desc>The null hypothesis: percentage of dilation with 400µg ≥ percentage of dilation with 200µg + 25% Alternative hypothesis: percentage of dilation with 400µg - 25% &lt; percentage of dilation with 200µg</p_value_desc>
            <method>difference between proportions</method>
            <method_desc>difference between percentages and 95% confidence interval</method_desc>
            <param_type>treatment difference</param_type>
            <param_value>25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>97.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin was determined by ⅓ of the difference between the 400µg effect (96.7%), compared to the 200 µg dose (23.3%), i.e. 73.4 / 3 = 24.46%</non_inferiority_desc>
            <p_value>0.004</p_value>
            <method>Chi-squared</method>
            <param_type>Difference between proportions</param_type>
            <param_value>0.1146</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.037</ci_lower_limit>
            <ci_upper_limit>0.192</ci_upper_limit>
            <estimate_desc>The difference between both groups was 11.5% (95%CI = 3.7% to 19.2%)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Presence of a Uterine Cervical Canal With ≥8 mm of Dilation</title>
        <description>This outcome measures how many mm of dilation the cervical canal has before the procedure. Cervical permeability (≥8 mm of dilation, used as a cut-off) was measured using Karman cannulas, from higher to low diameter.</description>
        <time_frame>Baseline before Manual Vacuum Aspiration procedure</time_frame>
        <population>Intention to Treat (all patients assigned to 400mg or 200µg of misoprostol)</population>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol 400 µg</title>
            <description>Misoprostol 400 µg 6 hours before intrauterine suction&#xD;
Misoprostol 400 µg: evaluate the required cervix dilation in the moment of the intrauterine suction</description>
          </group>
          <group group_id="O2">
            <title>Misoprostol 200 µg</title>
            <description>Misoprostol 200 µg 6 hours before intrauterine suction&#xD;
Misoprostol 200 µg: evaluate the required cervix dilation in the moment of the intrauterine suction</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Presence of a Uterine Cervical Canal With ≥8 mm of Dilation</title>
          <description>This outcome measures how many mm of dilation the cervical canal has before the procedure. Cervical permeability (≥8 mm of dilation, used as a cut-off) was measured using Karman cannulas, from higher to low diameter.</description>
          <population>Intention to Treat (all patients assigned to 400mg or 200µg of misoprostol)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inadequate (&lt;8 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adequate (≥8 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pain Score (VAS)</title>
        <description>Pain scores were assessed using a verbal analog scale (VAS), ranging from zero (no pain) to 10 (worst possible pain)</description>
        <time_frame>before Manual Vacuum Aspiration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol 400 µg</title>
            <description>Misoprostol 400 µg 6 hours before intrauterine suction&#xD;
Misoprostol 400 µg: evaluate the required cervix dilation in the moment of the intrauterine suction</description>
          </group>
          <group group_id="O2">
            <title>Misoprostol 200 µg</title>
            <description>Misoprostol 200 µg 6 hours before intrauterine suction&#xD;
Misoprostol 200 µg: evaluate the required cervix dilation in the moment of the intrauterine suction</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score (VAS)</title>
          <description>Pain scores were assessed using a verbal analog scale (VAS), ranging from zero (no pain) to 10 (worst possible pain)</description>
          <units>units on a scale - Verbal Analog Scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the MVA procedure until 6 hours after the procedure</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Misoprostol 400 µg</title>
          <description>Misoprostol 400 µg 6 hours before MVA</description>
        </group>
        <group group_id="E2">
          <title>Misoprostol 200 µg</title>
          <description>Misoprostol 200 µg 6 hours before MVA</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>uterine hemorrhage</sub_title>
                <description>Grade 2 - medical intervention indicated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>cervical laceration</sub_title>
                <description>Cervical laceration occurred with Pozzi forceps traction. Local suture was performed without further treatment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Technical problems with measurement leading to unreliable. Pregnancies with less than 8 weeks had their procedures completely done with small diameter Karman cannulas</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ricardo Francalacci Savaris</name_or_title>
      <organization>Dep. of Obstetrics and Gynecology, Universidade Federal do Rio Grande do Sul, Porto Alegre - RS - Brazil</organization>
      <phone>+5551997781966</phone>
      <email>rsavaris@hpca.edu.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

